BACKGROUND: Schizophrenic patients have a high comorbidity with substance use disorders. However, there are few studies on the efficacy of antipsychotics on psychopathology and on their repercutions on substance abuse. METHODS: All studies about pharmacological treatment of schizophrenic patients with substance abuse, included in Medline over the last ten years were analyzed. RESULTS: Of the 17 studies reviewed, most were prospective with small samples (< 30 patients, 5 studies) or case reports (7 studies). Objectives were to assess the efficacy on schizophrenic symptoms and the effect of the treatment on substance use. Atypical antipsychotics were the most studied. These pharmacological agents were effective at reducing symptoms and had few side effects. They also managed lo reduce substance abuse in 66-75% of patients. CONCLUSIONS: In spite of underlyng methodological problems of these studies, the findings suggest that atypical antipsychatics could be the treatment of choice in these patients.
BACKGROUND:Schizophrenicpatients have a high comorbidity with substance use disorders. However, there are few studies on the efficacy of antipsychotics on psychopathology and on their repercutions on substance abuse. METHODS: All studies about pharmacological treatment of schizophrenicpatients with substance abuse, included in Medline over the last ten years were analyzed. RESULTS: Of the 17 studies reviewed, most were prospective with small samples (< 30 patients, 5 studies) or case reports (7 studies). Objectives were to assess the efficacy on schizophrenic symptoms and the effect of the treatment on substance use. Atypical antipsychotics were the most studied. These pharmacological agents were effective at reducing symptoms and had few side effects. They also managed lo reduce substance abuse in 66-75% of patients. CONCLUSIONS: In spite of underlyng methodological problems of these studies, the findings suggest that atypical antipsychatics could be the treatment of choice in these patients.
Authors: Isabel Martínez-Gras; Janet Hoenicka; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel Angel Jiménez-Arriero; Elena Pérez-Hernandez; Israel Ampuero; Jose Antonio Ramos-Atance; Tomas Palomo; Gabriel Rubio Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-06-20 Impact factor: 5.270